{"entity":{"id":"idea-fund-value-based-patent-extension","kind":"idea","name":"Patent term extension scaled to proven survival gain","aka":[],"tldr":"A drug that adds years of life would earn extra years of market protection; one that adds a few weeks would earn none. Extensions would be lost if the promised benefit is not confirmed.","summary":"Supplementary protection or regulatory exclusivity would be granted in proportion to demonstrated overall survival or cure-rate gain over the best prior standard in a randomised trial (for example one additional year of exclusivity per six months of median overall survival gain, capped at five years, with bonuses for curative-intent settings). Approvals on surrogate endpoints receive provisional extension that is confirmed or revoked when survival data mature. Regulators already collect the necessary data; the change is to the reward, not the evidence standard.","asOf":"2026-09-08","links":[{"label":"Bottleneck evidence (Incentives reward me-too drugs and marginal gains): Upadhaya et al., PD1/PDL1 inhibitor clinical trial landscape (Nat Rev Drug Discov 2022)","url":"https://doi.org/10.1038/d41573-022-00030-4"}],"tags":[],"related":["idea-fund-benefit-indexed-exclusivity","idea-fund-cure-prize"],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":["os","pfs","accelerated-approval"],"trials":[],"people":[],"bottlenecks":["b-incentive-misalignment","b-trial-design"],"keyPapers":["paper-upadhaya-nat-rev-drug-discov"],"journals":[],"dependsOn":[],"notes":[],"hypothesis":"Linking exclusivity to survival gain shifts industry portfolios: within a decade the share of pivotal trials with overall survival as a primary or co-primary endpoint rises substantially, and the average survival gain of approved drugs increases relative to the prior decade.","rationale":"Exclusivity is the main lever of pharmaceutical reward and is currently flat with respect to benefit; paediatric exclusivity extensions show that firms respond strongly to even six months of added protection. Value-based rewards are the explicit goal of ESMO-MCBS and ASCO value frameworks, which are advisory today.","test":"Use economic modelling with historical approvals to calibrate the schedule, then run a legislated pilot in one jurisdiction for new oncology approvals over five years, tracking endpoint choice and benefit magnitude of filings.","maturity":"speculative","actor":"policy","cost":"small","horizonYears":6},"route":"/ideas/idea-fund-value-based-patent-extension/","neighbours":{"idea":[{"id":"idea-fund-cure-prize","kind":"idea","name":"A billion-dollar prize for the first durable cure of a lethal metastatic cancer","route":"/ideas/idea-fund-cure-prize/"},{"id":"idea-fund-duration-trial-exclusivity","kind":"idea","name":"Extra exclusivity for sponsors who run treatment-duration and de-escalation trials","route":"/ideas/idea-fund-duration-trial-exclusivity/"},{"id":"idea-fund-mcbs-linked-pricing","kind":"idea","name":"Launch prices indexed to the ESMO benefit scale, revisited when survival matures","route":"/ideas/idea-fund-mcbs-linked-pricing/"},{"id":"idea-fund-benefit-indexed-exclusivity","kind":"idea","name":"Shorter exclusivity for later-in-class drugs without added benefit","route":"/ideas/idea-fund-benefit-indexed-exclusivity/"},{"id":"idea-fund-conditional-transferable-voucher","kind":"idea","name":"Transferable priority vouchers for first-in-class drugs, with price conditions","route":"/ideas/idea-fund-conditional-transferable-voucher/"}],"term":[{"id":"accelerated-approval","kind":"term","name":"Accelerated approval","route":"/terms/accelerated-approval/"},{"id":"os","kind":"term","name":"Overall survival (OS)","route":"/terms/os/"},{"id":"pfs","kind":"term","name":"Progression-free survival (PFS)","route":"/terms/pfs/"}],"bottleneck":[{"id":"b-incentive-misalignment","kind":"bottleneck","name":"Incentives reward me-too drugs and marginal gains","route":"/bottlenecks/b-incentive-misalignment/"},{"id":"b-trial-design","kind":"bottleneck","name":"Trial design, endpoints and cost","route":"/bottlenecks/b-trial-design/"}],"paper":[{"id":"paper-upadhaya-nat-rev-drug-discov","kind":"paper","name":"Challenges and opportunities in the PD1/PDL1 inhibitor clinical trial landscape","route":"/key-papers/paper-upadhaya-nat-rev-drug-discov/"}]}}